By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Cubist
Pharmaceuticals Inc. v. Strides Inc. et al.
1:13-cv-01679;
filed October 9, 2013 in the District Court of Delaware

• Plaintiff: 
Cubist Pharmaceuticals Inc.
• Defendants: 
Strides Inc.; Agila Specialties Private Ltd.

Cubist
Pharmaceuticals, Inc. v. Strides, Inc. et al.
1:13-cv-06016;
filed October 9, 2013 in the District Court of New Jersey

• Plaintiff: 
Cubist Pharmaceuticals, Inc.
• Defendants: 
Strides, Inc.; Agila Specialities Private Ltd.

The
complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 6,468,967 ("Methods
for Administration of Antibiotics," issued October 22, 2002), 6,852,689
(same title, issued February 8, 2005), 8,058,238 ("High Purity
Lipopeptides," issued November 15, 2011), and 8,129,342 (same title,
issued March 6, 2012) following a Paragraph IV certification as part of Strides'
filing of an ANDA to manufacture a generic version of Cubist's Cubicin®
(daptomycin for injection, used for the treatment of skin infections caused by
certain Gram-positive microorganisms). 
View the Delaware complaint here.

Reckitt
Benckiser Pharmaceuticals Inc. et al. v. Watson Laboratories Inc. et al.
1:13-cv-01674;
filed October 8, 2013 in the District Court of Delaware

• Plaintiffs: 
Reckitt Benckiser Pharmaceuticals Inc.; RB Pharmaceuticals Ltd.; MonoSol Rx
LLC
• Defendants: 
Watson Laboratories Inc.; Actavis Inc.

Infringement
of U.S. Patent Nos. 8,475,832 ("Sublingual and Buccal Film Compositions,"
issued July 2, 2013) and 8,017,150 ("Polyethylene Oxide-Based Films and
Drug Delivery Systems Made Therefrom," issued on September 13, 2011)
following a Paragraph IV certification as part of Watson's filing of an ANDA to
manufacture a generic version of Reckitt Benckiser's Suboxone® (buprenorphine
hydrochloride and naloxone hydrochloride sublingual film, used for the
maintenance treatment of opioid dependence). 
View the complaint here.

Ferring B.V.
v. Mylan, Inc. et al.
2:13-cv-05909;
filed October 7, 2013 in the Eastern District of Pennsylvania

• Plaintiff: 
Ferring B.V.
• Defendants: 
Mylan, Inc.; Mylan Pharamaceuticals, Inc.; Mylan Institutional

Infringement
of U.S. Patent Nos. 8,487,005 ("Tranexamic Acid Formulations," issued
July 16, 2013), 7,947,739 (same title, issued May 24, 2011), 8,022,106 (same
title, issued September 20, 2011), and 8,273,795 (same title, issued September
25, 2012) following a Paragraph IV certification as part of Mylan's filing of
an ANDA to manufacture a generic version of Ferring's Lysteda® (tranexamic
acid, used to treat heavy menstrual bleeding). 
View the complaint here.